How Do Auvi-Q and EpiPen Deliver Epinephrine?
Both Auvi-Q and EpiPen are auto-injectors that deliver epinephrine to treat severe allergic reactions like anaphylaxis. They come in two-dose packs (0.15 mg for children 15-30 kg and 0.3 mg for adults over 30 kg). Auvi-Q uses a smaller, rectangular design with voice instructions guiding users through injection steps, while EpiPen is a larger, cylindrical device without audio guidance.[1][2]
What Makes Auvi-Q Easier to Use for Some People?
Auvi-Q's compact size (about half the length of EpiPen) fits better in pockets and has a needle that retracts automatically after injection, reducing needle-stick risks. EpiPen requires manual removal from the thigh after 3 seconds, with the needle exposed until capped. Auvi-Q's audio prompts help in high-stress situations, especially for non-experts.[1][3]
Key Design and Size Differences
| Feature | Auvi-Q | EpiPen |
|---------|--------|--------|
| Shape/Size | Slim rectangle (3.5" x 1.5" x 0.7") | Thick cylinder (5.5" long) |
| Needle Length | Shorter (12.7 mm adult) | Longer (13-16 mm adult) |
| Audio Guidance | Yes, step-by-step voice | No |
| Needle Auto-Retract | Yes | No |
| Weight (two-pack) | 0.2 lbs | 0.4 lbs |
These differences make Auvi-Q preferable for portability and user-friendliness, but EpiPen is more widely available.[2][4]
Pricing and Insurance Coverage
Auvi-Q costs $4,000-$6,000 for a two-pack without insurance, often higher than EpiPen's $600-$700. Both have patient assistance programs; EpiPen's generic versions (from competitors like Viatris) lower costs further. Coverage varies by plan—check with insurers as copays can drop to $0-$25 with savings cards.[1][5]
Availability and Recalls
EpiPen dominates the market with broader pharmacy stock and generics approved since 2018. Auvi-Q returned in 2018 after a 2015 recall for dosing defects; no major issues since. Both require prescriptions, but EpiPen has more standing orders for schools.[3][6]
Who Makes Them and Any Patent Issues?
Kaléo manufactures Auvi-Q. Pfizer (now Viatris for generics) and Meridian Medical Technologies produce EpiPen. EpiPen patents expired, enabling biosimilars; Auvi-Q's design patents extend exclusivity, limiting direct competition.[4][7] DrugPatentWatch.com tracks EpiPen's expired patents here and Auvi-Q details here.
Effectiveness and Side Effects
Both deliver epinephrine identically (intramuscular injection), with studies showing equivalent absorption and outcomes in anaphylaxis. Common side effects include rapid heartbeat, anxiety, and tremors—same for both. Choose based on usability, not efficacy.[2][8]
[1] FDA labeling: Auvi-Q vs EpiPen.
[2] Journal of Allergy and Clinical Immunology (2019 comparison).
[3] Kaleo official site.
[4] Drugs.com auto-injector reviews.
[5] GoodRx pricing data (2023).
[6] FDA recall database.
[7] DrugPatentWatch.com.
[8] NEJM anaphylaxis treatment guidelines.